Drugs / glucose-dependent insulinotropic peptide
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| — | NCT03556098 Comparator | Feb 2019 → Feb 2020 | type 1 diabetes mellitus | Steno Diabetes Center Copenhagen | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | glucose-dependent insulinotropic peptide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03556098 ↗ |
| Known as | glucose-dependent insulinotropic polypeptide | “In the present project the investigators will evaluate whether glucagonotropic properties of the gut-derived incretin hormone glucose-dependent insulinotropic polypeptide (GIP)...” NCT03556098 ↗ |
| Modality | Peptide | “gut-derived incretin hormone glucose-dependent insulinotropic polypeptide (GIP)” NCT03556098 ↗ |